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IMMUNOLOCALIZATION OF BASIC FIBROBLAST GROWTH FACTOR RECEPTORS IN INTERNAL 
THORACIC ARTERY AND SAPHENOUS VEIN GRAFTS 
Kyriakos St. Rammos, MD, and George J. Koullias, MD, Thessaloniki, Greece 
Basic fibroblast growth factor (bFGF), a 146-amino 
acid peptide with a strong affinity for heparin, has been 
found to induce mitogenic responses of endothelial 1 and 
vascular smooth muscle cells, augmenting their migratory 
biochemical phenotypes, 2 and inducing capillary blood 
vessel growth. 3Because of these mitogenic, migrating, and 
angiogenic properties, bFGF has ben inferred by several 
investigators to play a central role in pathobiochemical 
models of intimal hyperplasia nd consequent vascular 
remodeling.2, 4 The biologic actions of bFGF are exerted 
through its interaction with two different bFGF receptor 
(bFGFR) classes, which are located either on the target- 
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cell membrane (high-affinity bFGFRs) or in the extracel- 
lular matrix (low-affinity bFGFRs). 
The superiority in long-term patency of internal tho- 
racic artery (ITA) grafts versus aphenous vein (SV) grafts 
is in part attributable to the advantageous histologic and 
biologic characteristics of the former. These characteris- 
tics conduce to the absence of significant intimal hyper- 
plasia and atherosclerotic changes. Because of the previ- 
ously mentioned role of bFGF in vascular emodeling, we 
studied immunohistochemically the expression bFGFRs 
in ITA and SV tissue samples obtained from patients 
during coronary artery bypass grafting. 
Methods. Seventy-six patients undergoing coronary ar- 
tery bypass grafting with both ITA and SV conduits were 
recruited for this study. After median sternotomy, graft 
preparation, and graft harvesting, two 3 mm long vascular 
portions (one arterial and one venous) were obtained 
from the distal parts of the two grafts for each patient, 
placed immediately in neutral 10% formalin, and subse- 
quently embedded in paraffin. Two 5 p~m thick tissue 
sections for each patient (one ITA and one SV) were 
subjected to a three-stage avidin-biotin immunoperoxi- 
dase staining technique with the use of an anti-bFGFR 
monoclonal antibody that selectively binds to the high- 
Fig. 1. Strong endothelial SV graft bFGFR immunostaining. Arrows indicate brownish immunostaining 
(original magnification × 140). 
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Fig. 2. Intense vasa vasorum bFGFR presence in the periadventitial connective tissue of ITA graft. Arrows 
indicate brownish immunostaining (original magnification ×200). 
affinity bFGFRs (Ab-1; Oncogene Science, Inc., Union- 
dale, N.Y.). Negative control sections were prepared by 
replacing the primary antibody with normal swine serum, 
and sections from previously known positive prostatic 
carcinoma tissue were used as positive controls. 
The derived results were then assessed with regard to 
the presence of immunostaining in the three layers of the 
vascular wall and the adjacent periadventitial connective 
tissue. The ~ test was used to define possible significant 
differences regarding the localization of immunostaining 
in the intima, media, or externa. Ap  value equal to or less 
than 0.05 was considered statistically significant. 
Results. In the endothelium, bFGFRs were found in 29 
SV grafts (40.84%) and in eight ITA grafts(10.8%; p < 
0.05; Fig. 1). In the media, bFGFR immunoreactivity was 
detected in 47 (66.19%) of the SVs and was absent in the 
vascular smooth-muscle c lls of the ITA (p < 0.05). In the 
adventitia, 61 (85.91%) of the SV grafts and 48 (64.86%) 
of the ITA grafts had positive staining for bFGFR. When 
sole focus was placed on the small periadventitial vessels, 
however, the bFGFR immunoreactivity was found to be 
located exclusively in the ITA grafts (36 ITA grafts 
[48.64%] vs one SV graft [1.38%]; Fig. 2). 
Discussion. Until now, histologic differences, such as 
thicker media and an incomplete internal elastic lamina, 
and biochemical differences, including increased throm- 
boxane A2 and decreased prostacyclin and nitric oxide 
production, were the chief explanations given for the 
clinically established inferiority in long-term patency rates 
of SV versus ITA grafts. The results of this study indicate, 
at an immunohistochemical level of accuracy, that ITA 
and SV have an important molecular biologic difference. 
SV has a significantly greater presence of bFGF receptors 
in the endothelium and in the muscularis than does ITA. 
This difference between SV and ITA was also noted in 
a recent animal study by Nguyen and colleagues/ They 
stated that because increased levels of bFGF in the vessel 
wall of injured vessels were shown to accelerate the 
intimal hyperplasia process, the increased number Of 
bFGF receptors in SV (found both in their study and in 
our own) might trigger the same process. These increased 
bFGFR levels in the SV wall could explain the inferiority 
of long-term results of SV as a coronary bypass conduit. 
Further molecular studies are required to elucidate the 
role of bFGF in intimal hyperplasia. We hope that insight 
into the mechanism described here will, in the near future, 
provide clinicians with molecular tools to help prevent or 
delay the process of SV graft failure. 
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